Inhibition of CYP1 by 7,8-dehydrorutaecarpine and its methoxylated derivatives

Journal of Food and Drug Analysis

Volumn 15, Issue 4, 2007, Pages 480-487

  Tseng, Jen Chih ^a,b   Don, Ming Jaw ^a   Lewis, David F V ^c   Wang, Shu Yun ^a   Ueng, Yune Fang ^a,d  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^b CHINESE CULTURE UNIVERSITY   (Taiwan)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

7,8 dehydrorutaecarpine; CYP1; Inhibition; Selectivity

Indexed keywords

1 METHOXY 7,8 DEHYDRORUTAECARPINE; 1 METHOXYRUTAECARPINE; 10 METHOXY 7,8 DEHYDRORUTAECARPINE; 10 METHOXYRUTAECARPINE; 2 ETHOXY 7,8 DEHYDRORUTAECARPINE; 2 ETHOXYRUTAECARPINE; 2 METHOXY 7,8 DEHYDRORUTAECARPINE; 2 METHOXYRUTAECARPINE; 3 METHOXY 7,8 DEHYDRORUTAECARPINE; 4 METHOXY 7,8 DEHYDRORUTAECARPINE; 7,8 DEHYDRORUTAECARPINE; ALKALOID; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; HETEROCYCLIC COMPOUND; PLANT MEDICINAL PRODUCT; RUTAECARPINE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; IC 50; MOLECULAR MODEL; STRUCTURE ANALYSIS;

EID: 40749098602     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Guengerich, F. P. 1995. Human cytochrome P450. In "Cytochrome P450". pp 473-535. Ortiz de Montellano, P. R. ed. Plenum Press, New York.
2. Lewis, D. F. V., Lake, B. G., Dickins, M., Ueng, Y. F. and Goldfarb, P. S. 2003. Homology modeling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica 33: 239-254.
3. Kim, S., Ko, H., Park, J. E., Jung, S., Lee, S. K., and Chun, Y. J. 2002. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J. Med. Chem. 45: 160-164.
4. Lewis, D. F. V. and Lake, B. G. 1996. Molecular modeling of CYP1A subfamily members based on an alignment with CYP102: Rationalization of CYP1A substrate specificity in terms of active site amino acid residues. Xenobiotica 16: 723-753.
5. Shen, J. R. 1999. Pharmacological effects of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Cardiovasc. Drug Rev. 17: 237-245.
6. Don, M. J., Lewis, D. F. V., Wang, S. Y., Tsai, M. W. and Ueng, Y. F. 2003. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. Bioorg. Med. Chem. Lett. 13: 2535-2538.
7. Bergman, J. and Bergman, S. 1985. Studies of rutaecarpine and related quinazolinocarboline alkaloids. J. Organic Chem. 50: 1246-1255.
8. Narayanan, K., Schindler, L. and Cook, J. M. 1991. Carboxyl-Mediated Pictet-Spengler Reaction. Direct Synthesis of 1,2,3,4-Tetrahydro-β-carbolines from Tryptamine-2-carboxylic Acids. J. Organ. Chem. 56: 359-365.
9. Danieli, B., Palmisano, G., Rainoldi, G. and Russo, G. 1974. 1-Hydroxyrutaecarpine from Euxylophora Paraënsis. Phytochemistry 13: 1603-1606.
10. Yang, L. M., Chen, C. F. and Lee, K. H. 1995. Synthesis of rutaecarpine and cytotoxic analogues. Bioorg. Med. Chem. Lett. 5: 465-468.
11. Parikh, A., Gillam, E. M. J. and Guengerich, F. P. 1997. Drug metabolism by Escherichia coli expressing human cytochrome P450. Natur. Biotech. 15: 784-788.
12. Omura, T. and Sato, R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemeprotein nature. J. Biol. Chem. 239: 2370-2379.
13. Pohl, R. J. and Fouts, J. R. 1980. A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal. Biochem. 107: 150-155.
14. Gradelet, S., Astrog, P., Pineau, T., Canivenc, M. C., Siess, M. H., Leclerc, J. and Lesca, P. 1997. Ah receptor-dependent CYP1A induction by two carotenoids, canthaxanthin and β-apo-8′-carotenal with no affinity for the TCDD binding site. Biochem. Pharmacol. 54: 307-315.
15. Shimada, T., Gillam, E. M. J. Sutter, T. R., Strickland, P. T., Guengerich, F. P. and Yamazaki, H. 1997. Oxidation of Xenobiotics by Recombinant Human Cytochrome P450 1B1. Drug Metab. Dispos. 25: 617-622.
16. Chaudhary, A. and Willett, K. L. 2006. Inhibition of human cytochrome CYP1 enzymes by flavonoids of St. John's wort. Toxicol. 217: 194-205.
17. Liu, J., Ericksen, S. S., Besspiata, D., Fisher, C. W. and Szklarz, G. D. 2003. Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: Case of residue 382. Drug Metab. Dispos. 31: 412-420.
18. Szklarz, G. D. and Paulsen, M. D. 2002. Molecular modeling of cytochrome P4501A1: Enzyme-substrate interactions and substrate binding affinities. J. Biomol. Struc. Dynam. 20: 155-162.
19. Lewis, D. F. V., Lake, B. G., George, S. G., Dickins, M., Eddershaw, P. J., Tarbit, M. H., Bereford, A. P., Goldfarb, P. S. and Guengerich, F. P. 1999. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 139: 53-79.